These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26256696)

  • 1. Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
    Blanco B; Herrero-Sánchez C; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
    Int Immunopharmacol; 2015 Sep; 28(1):675-85. PubMed ID: 26256696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
    Pereira JK; Machado-Neto JA; Lopes MR; Morini BC; Traina F; Costa FF; Saad ST; Favaro P
    Eur J Cancer; 2015 Sep; 51(14):2076-85. PubMed ID: 26238016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
    Safaroghli-Azar A; Bashash D; Kazemi A; Pourbagheri-Sigaroodi A; Momeny M
    Eur J Pharmacol; 2019 Jan; 842():89-98. PubMed ID: 30401630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
    Ren H; Guo H; Thakur A; Zhang S; Wang T; Liang Y; Shi P; Gao L; Liu F; Feng J; Chen T; Yang T; Shang D; Liu JJ; Xu F; Chen M
    Oncotarget; 2016 Oct; 7(41):67277-67287. PubMed ID: 27572309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest.
    Sadeghi S; Esmaeili S; Pourbagheri-Sigaroodi A; Safaroghli-Azar A; Bashash D
    Turk J Haematol; 2020 Aug; 37(3):167-176. PubMed ID: 32160736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
    Bashash D; Safaroghli-Azar A; Delshad M; Bayati S; Nooshinfar E; Ghaffari SH
    Int J Biochem Cell Biol; 2016 Oct; 79():308-317. PubMed ID: 27599915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms.
    Blanco B; Herrero-Sánchez MC; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
    Immunol Res; 2015 Jun; 62(2):175-88. PubMed ID: 25869396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
    Bashash D; Delshad M; Safaroghli-Azar A; Safa M; Momeny M; Ghaffari SH
    Int J Biochem Cell Biol; 2017 Oct; 91(Pt A):1-8. PubMed ID: 28834761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
    Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; Corchete LA; San Miguel JF; Del Cañizo C; Blanco B
    J Hematol Oncol; 2016 Oct; 9(1):113. PubMed ID: 27765055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
    Matas-Céspedes A; Rodriguez V; Kalko SG; Vidal-Crespo A; Rosich L; Casserras T; Balsas P; Villamor N; Giné E; Campo E; Roué G; López-Guillermo A; Colomer D; Pérez-Galán P
    Clin Cancer Res; 2014 Jul; 20(13):3458-71. PubMed ID: 24799524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
    Koul D; Fu J; Shen R; LaFortune TA; Wang S; Tiao N; Kim YW; Liu JL; Ramnarian D; Yuan Y; Garcia-Echevrria C; Maira SM; Yung WK
    Clin Cancer Res; 2012 Jan; 18(1):184-95. PubMed ID: 22065080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
    Qiu Z; Yue S; Chang J; Wang G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Jul; 32(7):936-9. PubMed ID: 27363276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
    Lonetti A; Antunes IL; Chiarini F; Orsini E; Buontempo F; Ricci F; Tazzari PL; Pagliaro P; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Barata JT; Martelli AM
    Leukemia; 2014 Jun; 28(6):1196-206. PubMed ID: 24310736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
    Yaguchi S; Fukui Y; Koshimizu I; Yoshimi H; Matsuno T; Gouda H; Hirono S; Yamazaki K; Yamori T
    J Natl Cancer Inst; 2006 Apr; 98(8):545-56. PubMed ID: 16622124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
    Zang C; Eucker J; Liu H; Coordes A; Lenarz M; Possinger K; Scholz CW
    Leuk Lymphoma; 2014 Feb; 55(2):425-34. PubMed ID: 23721513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of BKM120 and BEZ235 against Lymphoma Cells.
    Civallero M; Cosenza M; Pozzi S; Bari A; Ferri P; Sacchi S
    Biomed Res Int; 2015; 2015():870918. PubMed ID: 26557706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
    Pivonello C; Patalano R; Solari D; Auriemma RS; Frio F; Vitulli F; Grasso LFS; Di Cera M; De Martino MC; Cavallo LM; Cappabianca P; Colao A; Pivonello R
    Endocrine; 2018 Dec; 62(3):663-680. PubMed ID: 30066286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
    Jin L; Jin MH; Nam AR; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Lett; 2017 Dec; 411():162-170. PubMed ID: 29024814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.